Clinical and Experimental Dermatology最新文献_第9页

The NHS two week wait skin cancer referral pathway: analysis and recommendations for process improvement. 国家医疗服务系统皮肤癌两周等待转诊路径：分析与流程改进建议》（NHS two week wait skin cancer referral pathway: analysis and recommendations for process improvement）。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-08-14 DOI: 10.1093/ced/llae323

Vishal Madan

{"title":"The NHS two week wait skin cancer referral pathway: analysis and recommendations for process improvement.","authors":"Vishal Madan","doi":"10.1093/ced/llae323","DOIUrl":"https://doi.org/10.1093/ced/llae323","url":null,"abstract":"Background: While pressures on the National Health Service skin cancer services have predated the COVID pandemic, the two -week-wait (2WW) skin cancer standards have deteriorated post-pandemic.Methods: The 2WW skin cancer pathway is analysed in this report utilising 4V typology and volume-variety matrix. Performance matrix of the 2WW skin cancer pathway and SIPOC analysis are also examined. Recommendations are provided following analysis and redesign of the process map of the pathway.Results: Process analysis has enabled identification of some of the limitations of the 2WW skin cancer pathway. This has led to recommendations including lesion assessment using artificial intelligence, single lesion assessment clinics and direct access skin surgery, all of which aim to expedite patient care and increase capacity in 2WW clinics.Conclusions: Process analysis of the 2WW skin cancer pathway provides useful insights and helps identify bottlenecks in the system. Recommendations following remapping the process offer potential solutions to help reducing time to referral and increasing capacity. These recommendations should help reduce waiting times for patients receiving initial diagnosis and subsequent definitive treatment for suspected skin cancers.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cosmetic Benefit in Mohs Surgery - an Overemphasized Theme? 莫氏手术的美容效果--一个被过分强调的主题？

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-08-14 DOI: 10.1093/ced/llae327

Sibel Demirel, Andrew Affleck

引用次数: 0

Patient and Caregiver Experience of Accessing Information on Hidradenitis Suppurativa through Social Media. 患者和护理人员通过社交媒体获取扁平苔藓信息的体验。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-08-14 DOI: 10.1093/ced/llae330

Anna Wolinska, Barry McGrath, Anne-Marie Tobin

引用次数: 0

A peculiar post-vaccination eruption. 接种疫苗后出现奇特皮疹。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-08-13 DOI: 10.1093/ced/llae315

Martina Volonté, Emanuele M Favale, Nicolò Di Giuli, Valeria Brazzelli, Stefania Barruscotti, Giacomo Fiandrino, Carlo F Tomasini, Camilla Vassallo

引用次数: 0

Histological features of immune cell infiltrate in lesional skin correlate with therapeutic response to dupilumab. 病变皮肤免疫细胞浸润的组织学特征与对杜匹单抗的治疗反应相关。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-08-13 DOI: 10.1093/ced/llae321

Niccolò Gori, Andrea Chiricozzi, Stefania Sfregola, Elena Ippoliti, Alessandro Di Stefani, Dalma Malvaso, Lucia Di Nardo, Francesco Federico, Gian Franco Zannoni, Ketty Peris

{"title":"Histological features of immune cell infiltrate in lesional skin correlate with therapeutic response to dupilumab.","authors":"Niccolò Gori, Andrea Chiricozzi, Stefania Sfregola, Elena Ippoliti, Alessandro Di Stefani, Dalma Malvaso, Lucia Di Nardo, Francesco Federico, Gian Franco Zannoni, Ketty Peris","doi":"10.1093/ced/llae321","DOIUrl":"https://doi.org/10.1093/ced/llae321","url":null,"abstract":"In the last decade, dupilumab, a monoclonal human antibody inhibiting IL-4/IL-13 signaling, has revolutionized the therapeutic management of moderate-to-severe atopic dermatitis (AD), permitting a long-term control of its signs and symptoms. The aim of this study was to identify histologic predictors of dupilumab efficacy after 16 weeks of treatment in a cohort of forty adult patients with moderate to severe AD who had undergone a skin biopsy for diagnostic purposes prior to treatment initiation. We found that EASI 75 and EASI 90 responses at week 16 were significantly associated with perivascular localization (OR=17.6, p=0.038) and lichenoid distribution (OR=31.8, p=0.025) of the immune infiltrate. Moreover, for each unit increase in the number (cells/m2) of CD4+ cells, the likelihood to achieve EASI75 response decreased by 1% (OR=0.99, p=0.037). In conclusion our study suggested a few pre-treatments qualitative and quantitative immunohistochemical features as promising markers predicting dupilumab response in AD patients.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of Clinician-Reported Outcome Measures for Alopecia Areata: A Systematic Scoping Review. 对脱发症临床医生报告结果的评估：系统性范围审查。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-08-08 DOI: 10.1093/ced/llae320

Emadodin Darchini-Maragheh, Anthony Moussa, Huw Rees, Leslie Jones, Laita Bokhari, Rodney Sinclair

{"title":"Assessment of Clinician-Reported Outcome Measures for Alopecia Areata: A Systematic Scoping Review.","authors":"Emadodin Darchini-Maragheh, Anthony Moussa, Huw Rees, Leslie Jones, Laita Bokhari, Rodney Sinclair","doi":"10.1093/ced/llae320","DOIUrl":"https://doi.org/10.1093/ced/llae320","url":null,"abstract":"Clinician-reported outcome measures (ClinROMs) are an important part of disease assessment in daily practice and clinical trials. There is a broad disagreement on the most appropriate ClinROM for a comprehensive assessment of alopecia areata (AA) severity. This paper aims to identify the currently available ClinROMs for AA through a systematic literature search, address their practical strengths and weaknesses, and identify the road ahead for future research. A search was conducted of the published, peer-reviewed literature via PubMed (Medline) and EMBASE (via Ovid) databases. Articles published in English within the last 23 years (post-2000) that objectively measured AA severity were included. We did not select scoring systems that were solely based on patient-reported outcomes (PROs). The literature search identified 1376 articles, of which 27 were chosen for full-text review. Based on our eligibility criteria, fourteen articles were identified, describing sixteen different ClinROMs. Five ClinROMs solely measured scalp hair loss (SALT, SALTⅡ, ALODEX, pSALT, and AA-IGA). Three trichoscopy-based ClinROMs assessed disease activity (AAPI, AAPS, and Coudability hair score). Six ClinROMs exclusively assessed non-scalp areas (BETA, BELA, ALBAS, ClinRO for Eyelash, Eyebrow, and Nail assessment). Two ClinROMs assessed both the scalp and beyond-scalp areas (AASI and AASc). The practical strengths and weaknesses of each assessment tool were described. Various practical limitations associated with established tools have impeded their universal implementation in routine clinical practice. There is a significant need for a holistic clinical severity scoring system to capture all the key severity identifiers beyond the involvement of the scalp.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficient topical treatments of cutaneous lupus erythematosus: A systematic review and network meta-analysis. 皮肤红斑狼疮的高效局部治疗：系统综述和网络荟萃分析。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-08-08 DOI: 10.1093/ced/llae236

Takemichi Fukasawa, Asako Yoshizaki-Ogawa, Atsushi Enomoto, Kiyoshi Miyagawa, Shinichi Sato, Ayumi Yoshizaki

{"title":"Efficient topical treatments of cutaneous lupus erythematosus: A systematic review and network meta-analysis.","authors":"Takemichi Fukasawa, Asako Yoshizaki-Ogawa, Atsushi Enomoto, Kiyoshi Miyagawa, Shinichi Sato, Ayumi Yoshizaki","doi":"10.1093/ced/llae236","DOIUrl":"https://doi.org/10.1093/ced/llae236","url":null,"abstract":"Objectives: Although cutaneous lupus erythematosus (CLE) has been treated with topical agents, there was no high-quality evidence of which agents were more effective, and which clinical scores were more suitable.Methods: On December 22nd, 2023, a search was conducted across five databases to identify randomized controlled trials (RCTs). Two authors independently screened the titles and abstracts of articles based on predetermined criteria. Selected articles were then assessed for inclusion in a blinded manner, with any disagreements resolved through consensus. Data were abstracted in duplicate, and a random-effects model was utilized for network meta-analysis. The certainty of the evidence was evaluated according to PRISMA guidelines, using the Grading of Recommendations Assessment, Development and Evaluation approach. The analysis was finalized in January 2024, with the primary outcome focused on the change in cutaneous lupus erythematosus disease area and severity index (CLASI) from baseline.Results: Seven RCTs involving 231 participants were analyzed. The network meta-analysis (NMA) revealed that 4% nicotinamide demonstrated the highest probability of achieving the intended outcomes, with a mean difference (MD) of 3.10 and a 95% confidence interval (CI) of 1.99-4.21. Additionally, 0.05% clobetasol, 2% nicotinamide, and 0.1% tacrolimus also exhibited statistically significant differences, with MDs of 2.30 and 95% CIs of 0.73-3.88; 2.30 and 0.97-3.63; and 1.30 and 0.03-2.57, respectively.Conclusion: As data with a high level of evidence, NMAs demonstrated that 4% nicotinamide, 0.05% clobetasol, 2% nicotinamide, and 0.1% tacrolimus are statistically significant topical agents. CLASI may be an appropriate outcome to evaluate drug efficacy in CLE.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":null,"pages":null},"PeriodicalIF":3.7,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypohidrotic ectodermal dysplasia in a family: expanding spectrum of LEF-1 related disorders. 一个家族的皮下外胚层发育不良：LEF-1相关疾病谱的扩大。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-08-07 DOI: 10.1093/ced/llae293

Ali Hassan, Fanny Morice-Picard, Victor Marin, Louis Lebreton, Julie Davaze-Schneider

引用次数: 0

Epidemiology, survival, and risk of subsequent primary malignancies in patients with digital papillary adenocarcinoma: a retrospective study of 213 patients in the Surveillance, Epidemiology, and End Results (SEER) Program. 数字乳头状腺癌患者的流行病学、存活率和继发原发性恶性肿瘤的风险：对监测、流行病学和最终结果 (SEER) 计划中 213 名患者的回顾性研究。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-08-06 DOI: 10.1093/ced/llae317

Tejas P Joshi, Arash Kimyai-Asadi

引用次数: 0

A case of dermatopathia pigmentosa reticularis masquerading as dyskeratosis congenita: the importance of nailing the correct diagnosis. 一例伪装成先天性角化障碍的网状色素性皮肤病：正确诊断的重要性。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2024-08-06 DOI: 10.1093/ced/llae310

Quynh Le, Anna Le Fevre, Tiong Yang Tan, Susan Robertson

引用次数: 0